Sorrento Therapeutics, Inc. Stock Deutsche Boerse AG
Stocks
8STN
US83587F2020
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 67.15M 58.75M 54.27M 49.95M 94.14M 6.46B 96.3M 647M 255M 3.16B 252M 247M 10.91B | P/E 2021 |
-3.2x | P/E 2022 | -0.65x |
|---|---|---|---|---|---|
| Enterprise Value | 152M 133M 123M 113M 213M 14.6B 218M 1.46B 575M 7.14B 570M 557M 24.65B | EV / Sales 2021 |
29.1x | EV / Sales 2022 | 7.89x |
| Free-Float |
98.65% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 day | +19.20% |
| Manager | Title | Age | Since |
|---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 61 | 2011-03-31 |
Scott Schaus
CTO | Chief Tech/Sci/R&D Officer | - | 2022-02-28 |
John Waldheim
LAW | General Counsel | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Henry Ji
CHM | Chairman | 61 | 2017-07-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +19.20% | -0.67% | - | - | 544K | |
| +0.24% | -1.54% | +52.85% | +71.85% | 53.83B | |
| -7.17% | -4.39% | +42.72% | +73.32% | 52.1B | |
| +0.80% | -6.31% | +5.62% | +417.78% | 23.48B | |
| -0.09% | -0.01% | -16.85% | -15.41% | 23.13B | |
| -5.95% | -2.58% | +29.53% | -9.47% | 19.36B | |
| -1.14% | +0.03% | +31.67% | -30.65% | 17.56B | |
| -5.16% | -7.00% | +168.44% | +314.96% | 15.2B | |
| -6.91% | -5.83% | +25.17% | +644.30% | 14.83B | |
| +0.43% | -1.03% | +25.75% | +189.74% | 14.06B | |
| Average | -0.58% | -2.62% | +40.54% | +184.05% | 25.95B | |
| Weighted average by Cap. | -2.80% | -2.36% | +39.55% | +143.13% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 52.9M 46.29M 42.76M 39.35M 74.17M 5.09B 75.87M 510M 201M 2.49B 199M 194M 8.6B | 62.84M 54.98M 50.79M 46.74M 88.1M 6.05B 90.12M 606M 238M 2.96B 236M 231M 10.21B |
| Net income | -428M -375M -346M -319M -601M -41.23B -614M -4.13B -1.62B -20.16B -1.61B -1.57B -69.6B | -573M -501M -463M -426M -803M -55.15B -822M -5.52B -2.17B -26.96B -2.15B -2.1B -93.08B |
| Net Debt | 111M 96.86M 89.47M 82.34M 155M 10.66B 159M 1.07B 420M 5.21B 416M 407M 17.99B | 84.53M 73.96M 68.32M 62.87M 119M 8.14B 121M 815M 320M 3.98B 317M 310M 13.73B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
